CompletedPhase 2

Study of the Safety and Efficacy of AMT-101 in Subjects With Pouchitis

United States22 participantsStarted 2021-02-05

Plain-language summary

Phase 2 Study Investigating the Efficacy of AMT-101 in Subjects with Chronic Antibiotic-resistant Pouchitis

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: • Chronic or recurrent pouchitis Exclusion Criteria: * Known gastrologic, or systemic condition that may compromise severity or diagnosis of disease. * History or current evidence of colonic or abdominal abnormalities. * Previous exposure to AMT-101 or similar and known hypersensitivity to AMT-101 or its excipients.

What they're measuring

Stool Frequency Response

Timeframe: 12 weeks

Histologic Healing

Timeframe: 12 weeks

Trial details

NCT IDNCT04741087

SponsorApplied Molecular Transport

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-03-11

View on ClinicalTrials.gov More Pouchitis trials